It is widely accepted that chimeric antigen receptor (especially bNAb-based CAR) engineered CD8+ T-cell therapy is a promising approach for curing HIV infection that is worth further exploration, even though there are limitations such as CAR T-cell expansion, persistence, off-target effect, and sCRS. The gene discussed is CD8A; the disease is HIV infectious disease.